{"id":"half-cyclophosphamide","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Hemorrhagic cystitis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL1200796","moleculeType":"Small molecule","molecularWeight":"279.10"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Cyclophosphamide is a nitrogen mustard alkylating agent that forms DNA cross-links, leading to cell death. The half-dose formulation reduces systemic toxicity while maintaining therapeutic efficacy, often used in combination regimens or for patients with reduced tolerance. This approach is particularly relevant in hematopoietic stem cell transplantation conditioning and certain autoimmune disease protocols.","oneSentence":"Half-dose cyclophosphamide is a reduced-intensity alkylating agent that cross-links DNA to kill rapidly dividing cells, particularly in cancer and autoimmune contexts.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:48.677Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer conditioning in hematopoietic stem cell transplantation"},{"name":"Autoimmune diseases (as part of reduced-intensity conditioning regimens)"}]},"trialDetails":[{"nctId":"NCT04187105","phase":"PHASE2","title":"BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2020-01-27","conditions":"Acute Leukemia, MDS","enrollment":27},{"nctId":"NCT01701674","phase":"NA","title":"Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2012-10-09","conditions":"Metastatic Melanoma","enrollment":13},{"nctId":"NCT04697940","phase":"PHASE1, PHASE2","title":"Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han weidong","startDate":"2021-04-15","conditions":"Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma, Decitabine-primed Tandem CD19/CD20 CAR T Cells","enrollment":33},{"nctId":"NCT06499025","phase":"EARLY_PHASE1","title":"Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)","status":"ENROLLING_BY_INVITATION","sponsor":"BGI, China","startDate":"2024-02-01","conditions":"AML, t(8;21), Neoantigen","enrollment":16},{"nctId":"NCT00619879","phase":"","title":"Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies","status":"COMPLETED","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2007-03-26","conditions":"Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute","enrollment":81},{"nctId":"NCT02880293","phase":"NA","title":"Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-08-23","conditions":"Hematologic Malignancy","enrollment":44},{"nctId":"NCT06224049","phase":"EARLY_PHASE1","title":"Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T","status":"RECRUITING","sponsor":"BGI, China","startDate":"2023-12-01","conditions":"T-cell Lymphoma","enrollment":6},{"nctId":"NCT05631912","phase":"PHASE1, PHASE2","title":"TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2023-06-30","conditions":"Non-hodgkin Lymphoma,B Cell","enrollment":38},{"nctId":"NCT00060346","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia","status":"TERMINATED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2004-10-05","conditions":"Lymphoma","enrollment":16},{"nctId":"NCT02685059","phase":"PHASE2","title":"Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2016-06","conditions":"Breast Cancer","enrollment":174},{"nctId":"NCT00854139","phase":"PHASE1","title":"Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2001-08","conditions":"Multiple Myeloma, End Stage Renal Disease","enrollment":10},{"nctId":"NCT02423928","phase":"PHASE1","title":"Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer","status":"COMPLETED","sponsor":"Alden Cancer Therapy II","startDate":"2015-05","conditions":"Prostate Cancer","enrollment":18},{"nctId":"NCT03892330","phase":"PHASE4","title":"Combination Therapy of Anthracyclines for Children With Nephroblastoma","status":"NOT_YET_RECRUITING","sponsor":"Shengjing Hospital","startDate":"2019-06-01","conditions":"0.5-14 Year Old Children With Nephroblastoma","enrollment":120},{"nctId":"NCT02936375","phase":"PHASE2","title":"The Iguratimod Effect on Lupus Nephritis (IGeLU)","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2017-09-07","conditions":"Lupus Nephritis","enrollment":120},{"nctId":"NCT00623077","phase":"PHASE1","title":"MT2004-30: Tomotherapy for Solid Tumors","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-08","conditions":"Brain and Central Nervous System Tumors, Kidney Cancer, Liver Cancer","enrollment":23},{"nctId":"NCT02446431","phase":"EARLY_PHASE1","title":"Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence","status":"RECRUITING","sponsor":"Miller Children's & Women's Hospital Long Beach","startDate":"2014-07","conditions":"Solid Tumor","enrollment":20},{"nctId":"NCT00580034","phase":"PHASE2","title":"Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath","status":"COMPLETED","sponsor":"David Rizzieri, MD","startDate":"2003-02","conditions":"Lymphoma, Myeloma, Leukemia","enrollment":176},{"nctId":"NCT01917578","phase":"PHASE3","title":"Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2008-08","conditions":"Breast Cancer","enrollment":4},{"nctId":"NCT00787761","phase":"PHASE2","title":"Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer","status":"COMPLETED","sponsor":"Northside Hospital, Inc.","startDate":"2007-04","conditions":"Myeloproliferative Disorders, Kidney Cancer, Leukemia","enrollment":24},{"nctId":"NCT00162656","phase":"PHASE3","title":"Treatment of Mature B-cell Lymphoma/Leukaemia","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"1996-05","conditions":"B-Cell Lymphoma","enrollment":848}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1248,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"half cyclophosphamide","genericName":"half cyclophosphamide","companyName":"Gustave Roussy, Cancer Campus, Grand Paris","companyId":"gustave-roussy-cancer-campus-grand-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Half-dose cyclophosphamide is a reduced-intensity alkylating agent that cross-links DNA to kill rapidly dividing cells, particularly in cancer and autoimmune contexts. Used for Cancer conditioning in hematopoietic stem cell transplantation, Autoimmune diseases (as part of reduced-intensity conditioning regimens).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}